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Abstract 
 
Glutamate serves multifaceted physiological functions in the CNS as the most abundant 
excitatory neurotransmitter and under pathological conditions as a potent neurotoxin. Elevated 
extracellular glutamate is known to play a central role in ischemic brain injury. The current study 
stems from our key observation demonstrating that induction of glutamate oxaloacetate 
transaminase (GOT), a glutamate-metabolizing enzyme in the brain, can attenuate stroke-induced 
injury. From the historical work of Hans Krebs, we know that GOT metabolism of glutamate 
generates TCA cycle intermediates in brain tissue. GOT catalyzes the transfer of the amino 
group from glutamate to the 4-carbon TCA cycle intermediate oxaloacetate to generate aspartate 
and the 5-carbon TCA cycle intermediate α-ketoglutarate. We thus proposed in a previous study 
that induction of GOT can utilize otherwise neurotoxic glutamate to support survival of ischemic 
glucose-starved neural cells. The aim of the current work is to identify the mechanisms of GOT 
induction. Emergent literature supports microRNAs (miRNAs) as key mediators of post-
transcriptional gene silencing. MicroRNAs comprise a novel class of small, noncoding 
endogenous RNAs that regulate gene expression by targeting mRNAs for degradation or 
translational repression. MicroRNA-9 (miR-9) is abundantly expressed in the brain, where it is 
predicted to target genes involved in glutamate metabolism. In the current work, we hypothesize 
that miR-9 targets GOT, resulting in post-transcriptional gene silencing. Furthermore, we 
hypothesize that inhibition of miR-9 upregulates GOT expression and enhances its 
neuroprotective properties. We recognize a therapeutic opportunity in which inhibition of miR-9 
could potentially lead to improved outcome for ischemic stroke patients.  
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Introduction 
Ischemic Stroke 
The impact of stroke on American society is staggering. Each year, more than 795,000 people 
are afflicted by and more than 130,000 people are killed by stroke1,2. This makes stroke the fifth 
leading cause of death in the United States1. In addition, the annual cost of healthcare services, 
medications, and missed days of work associated with stroke is approximately $34 billion3. 
Given the severity of the burden of stroke on people’s personal lives, the healthcare system, and 
the U.S. economy, it should not be surprising that the number of publications from stroke-related 
studies has doubled from 2005 to 20154. 
 
There are two types of stroke: ischemic and hemorrhagic (Figure 1). Hemorrhagic strokes are 
caused by rupturing of blood vessels in the brain, while ischemic stroke is characterized by a 
lack of blood flow to the brain. The latter may be caused by factors such as a blood clot that 
forms in the brain. In either case, the result is a shortage of oxygen and glucose delivery to neural 
cells. This is especially problematic considering that the brain uses 20-25% of the body’s total 
oxygen intake and that glucose is the primary metabolic fuel for neurons5. Of interest for this 
study are ischemic strokes, which constitute 87% of stroke cases3. 
 
Glucose and oxygen are both essential to the metabolic pathway that ultimately produces 
adenosine triphosphate (ATP). During glycolysis, glucose is oxidized to pyruvate. Pyruvate is 
then converted into acetyl-CoA, which enters the tri-carboxylic acid (TCA) cycle. This eight-
reaction cycle produces the electron donors NADH and FADH2, which feed into the electron 
transport chain (ETC). Molecular oxygen (O2) is the final electron acceptor in the ETC, and the 
proton gradient that is established across the inner mitochondrial membrane leads to the 
production of ATP by the enzyme ATP synthase. Overall, two molecules of ATP are produced 
during glycolysis, two are produced during the TCA cycle, and 28 are produced during oxidative 
phosphorylation by ATP synthase. 
 
ATP is necessary for the functioning of the sodium/potassium ATPase (Na+/K+ ATPase). This 
ion pump maintains proper ionic balance across the neuronal cell membrane by transporting 
three Na+ ions out of the cell and two K+ ions into the cell through the consumption of one ATP 
molecule. Under the hypoxic and hypoglycemic conditions of ischemia, ATP production is 
significantly reduced. This prevents the Na+/K+ ATPase from properly functioning, causing 
sodium and potassium to move passively down their electrochemical gradients. The cell 
membrane potential is normally approximately -70 mV, so the electrochemical gradient for Na+ 
into the cell is greater than the electrochemical gradient for K+ out of the cell. Na+ thus moves 
intracellularly faster than K+ moves extracellularly. The resulting ionic imbalance depolarizes the 
cell membrane. The change in membrane potential opens voltage-gated calcium (Ca2+) channels 
at the axon terminals of the presynaptic neuron. There is a large influx of Ca2+ into the 
presynaptic neuron, leading to the release of neurotransmitters into the synapse via synaptic 
vesicles. The neurotransmitter of interest for the current study is the amino acid glutamate, which 
is described below. 
 
Glutamate 
In addition to being one of the twenty amino acids found in eukaryotic proteins, glutamate also 
functions as an excitatory neurotransmitter in the mammalian central nervous system5. Under 
normal physiological conditions, glutamate plays an important role in cognitive processes such 
as learning and memory6. When glutamate is released into the synapse from vesicles in the 
presynaptic neuron, it binds to ionotropic receptors on the postsynaptic cell membrane (Figure 
2). These include N-methyl-D-aspartic acid (NMDA) and DL-α-amino-3-hydroxy-5-methyl-4-
isoxazole propionic acid (AMPA)5. The binding of glutamate to NMDA and AMPA initiates an 
action potential in the postsynaptic neuron and further propagates signal transduction. In order to 
prevent overstimulation of the glutamatergic receptors, glutamate is cleared from the synapse by 
a group of transmembrane proteins called excitatory amino acid transporters (EAATs)5. While 
different members of this protein family are found on both neurons and glial cells, EAAT2—
which is present in astrocytes—is the primary transporter of glutamate from the synapse7,8.  
 
Under the pathological conditions of ischemic stroke, glutamate becomes neurotoxic due to its 
accumulation in the synapse (Figure 3). In the absence of ATP production, depolarization of the 
presynaptic neuron leads to an influx of calcium, causing an excessive release of glutamate from 
presynaptic vesicles. In addition, the EAATs are active transporters, moving glutamate 
intracellularly against its concentration gradient. These transporters fail to function properly 
under ischemic conditions due to the lack of ATP production. Glutamate thus moves down its 
concentration gradient from the astrocytes to the extracellular space, further exacerbating 
glutamate accumulation at the synapse5. 
 
The excessive glutamate levels overwhelm the chemically-gated AMPA receptors. AMPA is an 
ion channel that opens upon binding to glutamate, leading to the influx of positive ions into the 
postsynaptic neuron. The resulting increase in cell voltage opens the voltage-gated NMDA 
receptors, which also function as ion channels. Excessive levels of calcium flow intracellularly 
through these receptors and activate proteases, endonucleases, phospholipases, and nitric oxide 
synthase, the latter leading to the production of reactive oxygen species (ROS) such as nitric 
oxide, superoxide, and hydrogen peroxide. The activation of these enzymes and ROS causes 
oxidative stress by reacting with the cell’s DNA, plasma membrane, cytoskeleton, and other 
structures vital to the cell’s survival. The cell ultimately dies as a result5. Glutamate thus plays an 
important role in the pathophysiological cascade that leads to the necrosis that is characteristic of 
ischemic stroke (Figure 4). 
 
Given glutamate’s neurotoxic role in ischemic stroke, it is not surprising that a variety of studies 
have been performed with the goal of reducing glutamate accumulation at the synapse during 
ischemia. These studies have largely focused on targeting the transmembrane proteins that 
directly interact with glutamate at the synapse5. Drugs have been designed with the intention of 
blocking glutamate receptors, blocking ion channels, or upregulating the expression of EAATs. 
While these research efforts have had success in preclinical trials, they have failed to translate 
into clinical success9,10,11. What these studies have in common is that they are attempting to 
address the downstream events of the ischemic cascade without addressing the original problem: 
lack of glucose delivery to the brain. Without glucose, the processes of glycolysis, the TCA 
cycle, and oxidative phosphorylation which produce ATP cannot take place. However, cells are 
capable of metabolizing other compounds under hypoglycemic conditions, including amino acids 
such as glutamate. Glutamate can be metabolized into the TCA cycle by an enzyme called 
glutamate oxaloacetate transaminase (GOT). This enzyme and its implications in the current 
study are described below. 
Glutamate Oxaloacetate Transaminase (GOT) 
The current work is based on a transcriptome screening of mouse and rat brain during ischemic 
stroke previously performed by our lab. That study demonstrated that levels of the enzyme 
glutamate oxaloacetate transaminase (GOT) were significantly increased in the stroke-affected 
hemisphere in animals receiving supplemental oxygen (SO) (inhaling 100% O2) during ischemia 
compared to those exposed to normal room air (RA) conditions12. Thus, correction of hypoxia 
during ischemic stroke induces GOT expression. 
 
GOT catalyzes the transfer of the amino group from glutamate to the 4-carbon TCA cycle 
intermediate oxaloacetate to form the amino acid aspartate and the 5-carbon TCA cycle 
intermediate α-ketoglutarate (Figure 5). Thus, glutamate can serve as a substrate to allow a 
truncated version of the TCA cycle to proceed (Figure 6). The reaction between acetyl-CoA and 
oxaloacetate to form citrate, and the subsequent formations of cis-aconitate and isocitrate, are 
bypassed. 
 
Delivery of glucose to brain tissue is drastically reduced under ischemic conditions due to the 
lack of blood supply. Thus, neurons and glial cells are unable to utilize their primary metabolic 
fuel. During ischemic stroke, glutamate accumulates in the synapses at neurotoxic levels and 
contributes to the pathophysiological cascade that ultimately results in cell death. GOT is capable 
of metabolizing glutamate into a truncated version of the TCA cycle, a process that normally 
depends on the presence of glucose. Taking all of this together, our lab built off of the 
transcriptome screening study to propose that, under the hypoglycemic conditions of ischemic 
stroke, correction of hypoxia can induce GOT expression, allowing the enzyme to metabolize 
glutamate and protect the brain from stroke-induced injury13. 
 
In this study, rats were exposed to either RA conditions or SO during experimentally induced 
ischemic stroke. GOT mRNA expression, enzyme activity, and protein expression were 
significantly increased in the stroke-affected hemisphere of rats exposed to SO compared to the 
contralateral hemisphere and the stroke-affected hemisphere of RA controls (Figure 7). In 
addition, glutamate levels in the stroke-affected hemisphere of SO rats were significantly lower 
than that of RA controls. Rats exposed to RA conditions also experienced a reduction in ATP 
levels in the stroke-affected hemisphere compared to the contralateral, while ATP levels were 
approximately equal in both hemispheres for rats exposed to SO (Figure 8). These results 
support the idea that GOT metabolizes glutamate upon correction of hypoxia during ischemic 
stroke. 
 
The implications of GOT in ischemic stroke are relevant in mice as well, the model for the 
current work. The study described in the previous paragraph used a second in vivo model in 
which mice were subjected to ischemic stroke under SO conditions. One week before ischemia 
was induced, mice were given green fluorescent protein (GFP)-tagged lentiviral vectors 
containing either GOT overexpression, knockdown, or scramble (control) small-interfering RNA 
(siRNA). The control siRNA had no effect on GOT mRNA expression or lesion volume of the 
stroke-affected hemisphere. GOT overexpression significantly increased GOT mRNA expression 
and reduced the lesion volume of the stroke-affected hemisphere. In contrast, GOT knockdown 
resulted in death from ischemia-induced brain injury for five of the six mice receiving this 
vector. For the lone survivor, GOT mRNA expression was significantly reduced in the stroke-
affected hemisphere and the lesion volume was drastically increased (Figure 9). 
 
Our lab is now investigating other mechanisms of GOT induction. The current study proposes 
that GOT is a target of miR-9—a member of a larger class of RNAs known as microRNAs 
(miRNAs). 
 
microRNAs and miR-9 
MicroRNAs (miRNAs) are endogenous, noncoding RNA molecules approximately 22 
nucleotides in length. They play an important role in gene regulation in plants and animals. 
Specific functions of miRNAs have been elucidated in a variety of organisms, ranging in 
complexity from C. elegans to humans14.  
 
miRNA genes are transcribed primarily by RNA polymerase II, forming a precursor molecule 
called a pri-miRNA. After the pri-miRNA is transcribed, it is cleaved by the Drosha RNase III 
endonuclease14. The cut creates a stem loop secondary structure about 60-70 nucleotides in 
length. This miRNA precursor—known as a pre-miRNA—is transported from the nucleus to the 
cytosol using the nuclear export receptor Exportin-515,16. Once in the cytoplasm, the double-
stranded portion of the stem loop is recognized by the enzyme Dicer14. Dicer then cuts both 
strands, eliminating the loop and creating an imperfect duplex. Only one of the two strands will 
become the mature gene product: this strand is the miRNA, while the other strand is called the 
miRNA*17. The strands of the miRNA:miRNA* duplex are then separated14. The miRNA strand 
is loaded into the RNA-induced silencing complex (RISC), while the miRNA* strand is 
degraded. After the mature miRNA is loaded into the RISC, the enzyme complex is ready to act 
on a target mRNA. The miRNA targets an mRNA message for either degradation or translational 
repression by binding to the 3’-untranslated region (3’UTR) of the mRNA18. The pathway of 
miRNA processing—from transcription to mRNA targeting—is shown in Figure 10. 
 
The present study focuses on microRNA-9 (miR-9), which is specifically expressed in the central 
nervous system of vertebrates19. It has been found to play an important role in a number of 
neurodegenerative disorders, including Huntington’s disease20,21,22, Alzheimer’s disease23,24, 
amyotrophic lateral sclerosis (ALS)25, and Parkinson’s disease26. In mice and humans, the miR-9 
gene has three predicted stem loop precursor structures, which are denoted miR-9-1, miR-9-2, 
and miR-9-3. These three predicted stem loops—along with the mature miR-9 and miR-9* 
sequences—are depicted in Figure 11.  
 
As shown in Table 1, different miRNAs have been implicated in ischemic stroke in terms of risk 
factors for onset of stroke and components of the ischemic pathophysiological cascade27. In 
December 2015, a paper published by Wei et al. was made available on Pubmed ahead of print. 
It is the first publication to report a link between miR-9 and stroke28. This study showed that 
miR-9 is downregulated under the hypoxic and hypoglycemic conditions of ischemia, and that it 
mediates neuronal apoptosis under these conditions by targeting a gene called Bcl2l11. The 
current study also focuses on the implications of miR-9 in stroke, but from the more upstream 
perspective of restoring metabolic fuel for brain tissue in the absence of glucose. Here, we 
propose that the mRNA of GOT—the enzyme that we have previously shown to promote cell 
survival during ischemia by metabolizing neurotoxic glutamate into the TCA cycle—is a target 
of miR-9.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
Ischemic Stroke 
• Blockage of blood 
vessel in brain 
• 87% Occurrence 
• 7.6% Mortality Rate 
Hemorrhagic Stroke 
• Rupturing of blood vessel in 
brain 
• 13% Occurrence 
• 37.5% Mortality Rate 
Figure 1: Differences between Ischemic and Hemorrhagic Stroke 
  
 
 
 
 
 
 
 
 
 
 
 
  Figure 2: Tripartite synapse under physiological conditions. Under physiological conditions, glutamate serves as the most abundant excitatory 
neurotransmitter in the brain. Sequestered in vesicles of the pre-synaptic neuron, 
glutamate is released into the synaptic cleft upon depolarization. Once released, 
glutamate binds to ionotropic (i.e., NMDA, AMPA) and/or metabotropic 
receptors (i.e., mGluR1, mGluR5) of the post-synaptic neuron to potentiate 
signal transduction. Glutamate clearance from the synaptic cleft is primarily 
handled by astrocyte-specific excitatory amino acid transporters (i.e., 
EAAT2). Adapted from Ref 5. 
  
 
 
 
 
 
 
  
Figure 3: Tripartite synapse under pathological conditions of acute 
ischemic stroke. Under pathological conditions of cerebral ischemia, energetic 
failure leads to reversal of EAATs and accumulation of glutamate in the 
synaptic cleft. Excitotoxic stimulation of glutamate receptors results in chronic 
depolarization, sustained Ca2+ influx, and cell death. AMPA, DL-α-amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid; EAAT, excitatory amino acid 
transporter; NMDA, N-methyl-D-aspartic acid. Adapted from Ref 5. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Ischemic cascade in neural cells. Cerebral ischemia results in a 
pathological cascade of cellular events triggered by energetic failure that lead to 
glutamate excitotoxicity and culminate in cell death. Adapted from Ref 5. 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Glutamate oxaloacetate transaminase. GOT catalyzes the 
reversible transfer of an amino group (NH3+) from glutamate to the four-carbon 
TCA cycle intermediate oxaloacetate to generate aspartate and the five-carbon 
TCA cycle intermediate α-ketoglutarate. GOT, glutamate oxaloacetate 
transaminase; TCA, tri-carboxylic acid. Adapted from Ref. 5. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: GOT enables an abridged TCA cycle. In the absence of glucose 
during ischemic stroke, neural cells that lack glycogen stores must turn to 
alternative substrates to maintain cellular energetics. We hypothesize that GOT 
enables an abridged TCA cycle under conditions of stroke-induced 
hypoglycemia such that otherwise excitotoxic glutamate undergoes a role 
reversal to become a source of energy and survival factor. Adapted from Ref 5.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Correction of stroke-induced hypoxia increases GOT expression 
and activity at stroke site. The rodent brain transcriptome was compared 
between normoxic (RA) and SO groups. (A) Heat map—from 3281 genes with 
higher expression in SO-treated stroke tissue as compared to RA, GOT was 
identified as a gene target for the ability to metabolize Glu into tricarboxylic 
acid cycle intermediates. (B) GOT gene expression was validated in 
contralateral control (c), RA and SO neurons laser captured from 
cortex. (C) GOT activity and (D) immunostaining were significantly higher in 
SO than in RA stroke tissue. *p<0.05. c, control; Glu, glutamate; GOT, 
glutamate oxaloacetate transaminase; RA, room air; SO, supplemental oxygen. 
Adapted from Ref 13. 
  
 
 
 
 
 
 
 
 
 
 
Figure 8: SO lowered cortical Glu concentration and protected against loss 
of ATP in stroke affected brain tissue. S1 cortex in contralateral and stroke-
affected tissue after 90 min MCAO without reperfusion under RA or SO. 
Assays: (A) Glu concentration, (B) ATP/ADP, and (C) ATP% change. p<0.05: 
*control versus stroke, †RA stroke versus SO stroke. MCAO, middle cerebral 
artery occlusion. Adapted from Ref 13. 
  
 
 
 
 
Figure 9: GOT overexpression and knockdown influenced stroke outcome 
under SO conditions. GFP-tagged lentiviral vector delivered to cortex 
transduced 25–35 mm3 of brain tissue covering the stroke area. (A, B) GFP and 
NeuN (red) coexpression in S1 cortex of stroke hemisphere (arrow) was >95% 
compared to control. One week after lentiviral injection, mice were subjected to 
MCAO with correction of hypoxia by SO during cerebral ischemia. (C–E) GOT 
mRNA expression from right (stroke) and left (contralateral control) 
hemisphere and representative 11.7T 48 h MRI of (C) control (iLenti-GFP 
scrambled siRNA), (D) GOT overexpression, and (E) GOT knockdown 
mice. (F) Digital planimetry of T2-weighted 48 h MRI was employed to 
determine stroke-induced lesion volume as percentage of 
hemisphere. (G) Successful MCAO was confirmed by laser Doppler flowmetry. 
Only one of six GOT knockdown mice survived to 48 h MRI. *p<0.05 control 
versus stroke. MRI, magnetic resonance imaging. Adapted from Ref 13. 
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Figure 10: miRNA Transcription, Maturation, and mRNA Targeting. 
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Figure 11: Secondary Stem Loop Structures of the Three Mouse miR-9 
Gene Products. The bases highlighted in pink indicate the sequences of the 5’ 
arm and the 3’ arm of the mature miRNA, which are the same for all three miR-
9 genes. Obtained from miRBase. 
  
 
 
 
 
 
 
 
miRNA Stroke Risk Factor/Event in 
Pathophysiological Cascade 
miR-2129,30 Atherosclerosis29,30 
miR-12631,32 Atherosclerosis31,32 
miR-3333 Hyperlipidemia33 
miR-125a-5p34 Hyperlipidemia34 
miR-15535,36 Hypertension35,36 
miR-22237,38 Plaque rupture37,38 
miR-21039,40 Plaque rupture39,40 
miR-15a41 Blood brain barrier disruption41 
miR-49742 Cell apoptosis42 
miR-928 Cell apoptosis28 
Table 1: Implication of miRNAs in Ischemic Stroke. 
Materials and Methods 
Cell Culture 
Mouse hippocampal HT4 neural cells were grown in Dulbecco’s modified Eagle medium 
supplemented with 10% fetal calf serum, 100 μg/mL streptomycin, 100 units/mL penicillin, and 
0.25 μg/mL amphotericin at 37oC in a humidified atmosphere of 95% air and 5% CO2. 
Immediately before starting the experiments, the culture medium was replaced with fresh 
medium containing the same supplement conditions43. 
 
Transfection  
HT4 neural cells (0.1 x 106 cells/well in 12-well plate) were seeded in antibiotic-free medium for 
24 hours before transfection. DharmaFECT 1 transfection reagent was used to transfect cells 
with miRIDIAN mmu-miR-9 mimic or miRIDIAN mmu-miR-9 inhibitor (Thermo Scientific 
Dharmacon RNA Technologies, Lafayette, CO, USA) according to the manufacturer’s 
instructions. miRIDIAN miR mimic or inhibitor negative control (Thermo Scientific Dharmacon 
RNA Technologies, Lafayette, CO, USA) were used for control transfections. After 72 hours, 
RNA or protein were isolated from the cells43. 
 
Dual Luciferase Assay 
After 72 hours of transfection with mmu-miR-9 mimic or mmu-miR-9 inhibitor, HT4 cells were 
transfected with 100 ng of pLuc-GOT—3’UTR plasmid (Signosis, Santa Clara, CA). 
Normalization was achieved by co-transfection with Renilla plasmid (10 ng). Cells were lysed 
after 24 hours, and luciferase activity was determined using the dual-luciferase reporter assay 
system (Promega, Madison, WI). Data are presented as ratio of Firefly:Renilla luciferase 
activity44. 
 
RNA Isolation and Real-Time PCR 
Total RNA was extracted using the miRVana miRNA Isolation Kit according to the 
manufacturer’s protocol (Ambion, Grand Island, NY, USA). Specific TaqMan assays for miRs 
and the TaqMan Micro-RNA Reverse Transcription Kit were used to determine miR expression, 
followed by real-time PCR using the Universal PCR Master Mix (Applied Biosystems, Grand 
Island, NY, USA). Levels of miRNA were quantified with the relative quantification method 
using miR-16 as the housekeeping miRNA. Relative quantification method 2 (ΔΔct) was 
employed for miRNA expression levels43. 
 
Western Blot  
After protein extraction, protein concentrations were determined using the BCA protein assay 
(Pierce Chemical Co., Rockford, IL). Samples (20-30 μg of protein/lane) were separated on a 
10% SDS-polyacrylamide gel electrophoresis, and probed with anti-GOT (1:1000, Abcam, 
Cambridge, MA). Membranes were probed with anti-GAPDH antibody to normalize (1:10000, 
Sigma-Aldrich, St. Louis, MO)43. 
 
Stereotaxic Delivery of Lentiviral Particles 
To knockdown miR-9, a 10-μL syringe connected to a motorized nano-injector (KD Scientific, 
Holliston, MA, USA) was used to deliver 5 μL of GFP-tagged miR-9 inhibitor lentiviral 
transduction particles or non-targeting scramble control lentiviral particles (1.0 x 108 IU/mL, 
Applied Biological Materials, Richmond, British Columbia) at a rate of 0.2 μL/minute by 
stereotaxic injection. Lentiviral particles were delivered to the somatosensory cortex (S1) of the 
anticipated stroke hemisphere using the following coordinates: –0.5mm posterior, +3.5mm 
lateral, and –1.0mm ventral to bregma. MCAO was performed on mice after 72 hours of 
delivery13. 
 
Mouse Stroke Model 
Focal cerebral ischemia was induced in 8- to 10-week-old C57BL/6 mice by the intraluminal 
suture method of middle cerebral artery occlusion (MCAO) for 60 minutes. Laser Doppler 
flowmetry (DRT4, Moor Instruments, Wilmington, DE, USA) was used to confirm successful 
MCAO (70±10% drop in MCA territory cerebral blood flow)43. 
 
Magnetic Resonance Imaging and Determination of Infarct Volume  
T2-weighted magnetic resonance imaging (MRI) was performed on mice 48 hours post-stroke 
using an 11.7 (500 MHz) MR system comprised of a vertical bore magnet (Bruker Biospin, 
Ettlingen, Germany) to determine infarct volume. To perform stroke-volume calculations, raw 
MRI images were converted to digital imaging and communications in medicine (DICOM) 
format and read into ImageJ software (NIH). After matched contrast enhancement of images in 
ImageJ, digital planimetry was performed by a masked observer to delineate the infarct area in 
each coronal brain slice. Infarct areas from brain slices were summed, multiplied by slice 
thickness, and corrected for edema-induced swelling to determine infarct volume13. 
 
 
Tissue Processing and Sectioning, Immunofluorescence, and Microscopy 
Immediately following MRI, mouse brain tissue was harvested, sliced using a brain matrix (Ted 
Pella, Redding, CA, USA) and embedded in optimal cutting temperature (OCT) compound. 
OCT-embedded frozen brain was sectioned at 12 μm and mounted onto slides. Coronal brain 
sections were stained with anti-GOT antibody (1:200, Abcam, Cambridge, MA). Stained 
sections were analyzed by fluorescence microscopy (Axiovert 200 M, Zeiss, Gottingen, 
Germany) and images were captured using Axiovert v4.8 software (Zeiss)43. 
 
Statistical Analysis 
Data are reported as mean±S.D. of at least three experiments. Difference in means was tested 
using Student’s t-test or one-way ANOVA followed by Scheffe’s post hoc test. p<0.05 was 
considered statistically significant43. 
 
 
 
 
 
 
 
 
 
 
Results 
The current work hypothesizes that miR-9 targets the glutamate-metabolizing, neuroprotective 
enzyme GOT. MicroRNAs bind to the 3’UTRs of the mRNAs of the genes that they regulate. 
This targets the mRNAs for either degradation or translational repression. We thus wanted to 
demonstrate that targeting of GOT mRNA by miR-9 was possible by computationally screening 
for sites of complementarity between miR-9 and the 3’UTR of GOT. Two different algorithms—
Targetscan Mouse (version 5.1) and miRanda—were used to search for such regions of 
complementarity. Both algorithms showed perfect complementarity between bases 24-30 of the 
3’UTR of GOT and bases 2-8 of miR-9 (Figure 12). Residues 2-8 of miRNAs are known to be 
particularly important in binding to mRNA targets29. This region of a miRNA is known as the 
seed sequence. Given that only the seed sequence of miR-9 shows complementarity with the 
3’UTR of GOT, the GOT mRNA would be referred to as a 5’-dominant seed-only target site29. 
This in silico approach therefore demonstrates that miR-9 and GOT have sufficient binding 
complementarity for targeting of the latter by the former to be possible. 
 
To test the hypothesis that miR-9 targets GOT, we employed an in vitro model and an in vivo 
model. For the former, mouse hippocampal HT4 cells were used. Experimental cells were 
transfected with either miRIDIAN mmu-miR-9 mimic to simulate upregulation of miR-9 
expression or miRIDIAN mmu-miR-9 inhibitor to simulate downregulation of miR-9 expression. 
Control cells were transfected with either control mimic or control inhibitor.  
 
After 72 hours of transfection, RNA or protein were isolated from HT4 cells. miR-9 expression 
levels were determined by real-time polymerase chain reaction (RT-PCR). As expected, miR-9 
expression was significantly increased in cells transfected with mmu-miR-9 mimic compared to 
controls (Figure 13A). Likewise, miR-9 expression was significantly reduced in cells transfected 
with mmu-miR-9 inhibitor compared to controls (Figure 13B). GOT expression levels in 
transfected cells were measured using Western blot. Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) was used as a housekeeping protein to normalize the data. GOT expression in cells 
transfected with mmu-miR-9 mimic was less compared to that in the control mimic cells (Figure 
13C). Conversely, GOT expression in cells transfected with mmu-miR-9 inhibitor was greater 
compared to that in control inhibitor cells (Figure 13D). This suggests that miR-9 and GOT 
expression levels are inversely related. 
 
To demonstrate that miR-9 targets GOT, mmu-miR-9 mimic cells and control mimic cells were 
co-transfected with pLuc-GOT—3’UTR plasmid and Renilla plasmid for 24 hours. The GOT 
plasmid contained Firefly luciferase as part of the construct, while the Renilla plasmid contained 
Renilla luciferase. After 24 hours, the cells were lysed and a dual luciferase assay was 
performed. The data were collected as the ratio of Firefly:Renilla luciferase enzyme activity. A 
greater ratio would correspond to a greater amount of GOT expression. The Firefly:Renilla 
luciferase ratio was found to be significantly lower in mmu-miR-9 mimic cells compared to 
mimic controls (Figure 14). The dual luciferase assay suggests that miR-9 targets GOT in vitro.  
 
GOT protects the brain from injury during ischemic stroke by metabolizing glutamate into the 
TCA cycle, which alleviates glutamate’s neurotoxicity. To examine miR-9 targeting of GOT in 
the context of ischemic stroke, C57BL/6 mice were employed as an in vivo model. The mice 
were first cranially injected with either a GFP-tagged miR-9 inhibitor lentiviral vector or a non-
targeting scramble control vector. These vectors were delivered to the somatosensory (S1) cortex 
of the anticipated the stroke-affected hemisphere via stereotaxic injection. After 72 hours of 
delivery, ischemic stroke was induced in the mice via MCAO for 60 minutes. T2-weighted MRI 
was employed to determine the lesion volume of the stroke-affected hemisphere 48 hours later. 
After MRI, the brains were removed from the skulls, embedded in OCT, sectioned onto slides, 
and stained with an anti-GOT antibody. 
 
Microscopic visualization of GFP (green) and GOT (red) in stroke-affected mouse brain 
confirmed successful delivery of lentiviral vectors. (Figure 15A). Furthermore, fluorescence 
microscopy allowed us to quantify GOT expression in the two groups. GOT expression was 
significantly upregulated in the brains of mice receiving the miR-9 inhibitor lentiviral vector 
compared to those receiving the scramble control (Figure 15B). These results support targeting 
of GOT by miR-9 in vivo. 
 
Our lab has previously shown that induction of GOT expression during ischemic stroke 
attenuates lesion volume in the stroke-affected hemisphere13. In the current study, T2-weighted 
MRI showed that stroke-induced lesion volume was significantly reduced in mice receiving the 
miR-9 inhibitor lentiviral vector compared to controls. The images obtained from MRI are 
shown in Figure 15C, and quantification of the lesion volume is shown in Figure 15D. Taken 
together, the results from the in vivo model not only demonstrate that miR-9 targets GOT, but 
that GOT’s neuroprotective properties in the context of ischemic stroke are enhanced when miR-
9 expression is inhibited. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: In silico sequence complementarity of GOT 3’ UTR and miR-9. 
Targetscan Mouse (ver 5.1) and miRanda were queried for complementarity of 
miR-9 binding to the 3’UTR of GOT (NM_010324). Both returned a single site 
of complementarity between bases 24-30 of the 3’UTR of GOT and based 2-8 
of miR-9. This corresponds to the seed sequence of miR-9. Vertical lines 
represent perfect complementary binding. 
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Figure 13: miR-9 targets GOT in vitro. Mouse hippocampal HT4 cells were 
transfected with either miRIDIAN mmu-miR-9 mimic, miRIDIAN miR-9 
inhibitor, control mimic, or control inhibitor. miR-9 expression levels were 
measured in cells 72 hours post-transfection. miR-9 expression was 
significantly increased in miR-9 mimic cells compared to controls (A), and 
significantly reduced in miR-9 inhibitor cells compared to controls (B). Western 
blot was used to determine relative levels of GOT expression. Here, GAPDH 
was used as a housekeeping protein to confirm gel loading efficacy. GOT 
expression was reduced in miR-9 mimic cells compared to controls (C), and 
increased in miR-9 inhibitor cells compared to controls (D). *p<0.05. 
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Figure 14: miR-9 targeting of GOT in vitro. After 72 hours of transfection, 
cells transfected with miRIDIAN mmu-miR-9 mimic or control mimic were co-
transfected with pLuc-GOT—3’UTR plasmid and control plasmid for 24 hours. 
The GOT plasmid construct contained Firefly luciferase, while the control 
plasmid construct contained Renilla luciferase. After 24 hours, a dual luciferase 
assay was performed to measure GOT activity. The data are reported as 
Firefly:Renilla luciferase activity, with a greater ratio corresponding to greater 
GOT expression. The ratio of Firefly:Renilla luciferase activity was 
significantly reduced in miR-9 mimic cells compared to controls. *p<0.01. 
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Figure 15: Inhibition of miR-9 upregulated GOT expression and reduced 
stroke-induced lesion volume. C57BL/6 mice were cranially injected with 
either GFP-tagged miR-9 inhibitor lentiviral particles or a non-targeting 
scramble control for 72 hours. Lentiviral vectors were delivered to the 
somatosensory cortex via stereotaxic injection. After 72 hours, ischemic stroke 
was induced via MCAO for 60 minutes. 48 hours after MCAO, T2-weighted 
MRI was performed, followed by removal and sectioning of the brain tissue for 
immunofluorescent analysis. Cells co-expressed GOT (red) and GFP (green), 
indicating successful uptake of lentiviral vectors (A). GOT expression was 
significantly increased in mice receiving miR-9 inhibitor lentiviral vector 
compared to controls (B). The lesion volume in the stroke hemisphere was 
significantly reduced mice receiving miR-9 inhibitor lentiviral vector compared 
to controls. (C) Representative images taken using T2-weighted MRI, (D) 
quantification of stroke-induced lesion volume. *p<0.05. 
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Discussion 
As previously mentioned, stroke is the fifth leading cause of death in the United States1. The 
impact of this disease on American society and the healthcare system has motivated our lab to 
investigate mechanisms of improving post-stroke outcome. Given glutamate’s well established 
role in the ischemic pathophysiological cascade, a myriad of studies have been carried out that 
have investigated ways to sequester neurotoxic glutamate from the synapse during stroke5. These 
include developing drugs that block the glutamatergic NMDA and AMPA receptors, block 
presynaptic calcium channels, or upregulate the EAATs that transport glutamate intracellularly 
from the synapse to glial cells. While these studies have shown promise in rodent models, they 
have so far failed to translate to clinical success9,10,11.  
 
A transcriptome screening previously performed by our lab demonstrated that correction of 
hypoxia during ischemic stroke induces expression of the glutamate-metabolizing enzyme GOT 
in the stroke-affected hemisphere of rats and mice12. GOT catalyzes the transfer of the amino 
group from glutamate to the 4-carbon TCA cycle intermediate oxaloacetate to form aspartate and 
the 5-carbon TCA cycle intermediate α-ketoglutarate. Subsequent work in our lab showed that 
SO therapy reduces glutamate levels and maintains normal ATP levels in the stroke-affected 
hemisphere of rats13. Furthermore, our lab demonstrated that lentiviral overexpression of GOT in 
the stroke-affected hemisphere of mice leads attenuates stroke-induced lesion volume, while 
knockdown of GOT exacerbates lesion volume13. These results support the idea that induction of 
GOT expression protects the brain from injury during ischemic stroke by metabolizing glutamate 
into the TCA cycle.  
 
While studies dealing with glutamatergic receptors, calcium channels, and glial transporters have 
solely focused on removing excess glutamate from the synapse, our approach addresses two 
major factors that contribute to the pathophysiological cascade of ischemic stroke. By 
metabolizing glutamate into the TCA cycle, GOT simultaneously sequesters glutamate from the 
synapse and converts it into a metabolic fuel that can restore ATP production in neurons under 
ischemic conditions. This is essential because the lack of blood flow prevents glucose—the 
brain’s primary metabolic fuel—from being delivered to the cells. 
 
The purpose of the current study was to investigate other factors that may influence GOT 
expression. miRNAs are a class of small non-coding RNAs that play an important role in gene 
regulation. They do so by binding to the 3’ UTR of the mRNAs of the genes that they target, 
leading to post-transcriptional gene silencing. miR-9 is abundantly expressed in brain tissue, and 
is predicted to target genes that play a role in glutamate metabolism. We therefore hypothesized 
that miR-9 targets GOT. The computational algorithms TargetScan Mouse and miRanda were 
used to search for regions of complementarity between the 3’UTR of GOT and miR-9. The seed 
sequence of miR-9 showed perfect complementarity with bases 24-30 of the 3’ UTR of GOT. No 
other regions of complementarity were found. This type of binding between a miRNA and its 
mRNA target is characteristic of a 5’-dominant seed-only target site, and is sufficient to allow for 
mRNA targeting. 
 
To biologically validate GOT as a target of miR-9, an in vitro and an in vivo model were 
employed. For the former, simulation of miR-9 overexpression in mouse hippocampal HT4 cells 
significantly decreased GOT expression. For the latter, inhibition of miR-9 in mice afflicted with 
ischemic stroke significantly increased GOT expression and attenuated stroke-induced lesion 
volume. These results support targeting of GOT by miR-9, and that miR-9 inhibition enhances 
GOT’s neuroprotective properties in the context of ischemic stroke. 
 
Future studies in our lab will investigate the effect miR-9 inhibition on post-stroke outcome in 
mice. This could be performed by assessing sensorimotor function in mice before and after 
MCAO. Metrics such as distance travelled and average speed could be measured in a controlled 
environment over a predetermined amount of time pre- and post-stroke. Statistical analysis of the 
data collected could then determine if there is a significant post-stroke difference in these metrics 
in mice receiving miR-9 inhibitor lentiviral particles compared to controls. With promising 
results, drugs can be designed to inhibit miR-9 expression. There is already an ongoing effort to 
investigate natural products, such as curcumin, that may inhibit miRNAs believed to play a role 
in cancer progression45. This approach may perhaps be applied in the context of ischemic stroke 
as well. Our work with GOT so far has shown promising results in the effort to protect the brain 
from injury under ischemic conditions. This work presents a potential therapeutic opportunity in 
which a mechanism of GOT induction—such as miR-9 inhibition—could lead to an improved 
outcome for patients who suffer an ischemic stroke. 
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